The emergence of neoadjuvant immune- over BRAF therapy in melanoma

Cancer. 2024 Oct 15;130(20):3409-3411. doi: 10.1002/cncr.35490. Epub 2024 Jul 22.

Abstract

Neoadjuvant therapy has emerged in high-risk stage III melanoma with immunotherapy improving long-term outcomes when compared with BRAF and MEK inhibition. Unmet needs remain surrounding optimal immunotherapy combinations, selection biomarkers and deintensification of treatment.

Publication types

  • Editorial

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / methods
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Melanoma* / immunology
  • Melanoma* / therapy
  • Neoadjuvant Therapy* / methods
  • Proto-Oncogene Proteins B-raf* / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf* / genetics
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / immunology
  • Skin Neoplasms / therapy

Substances

  • Proto-Oncogene Proteins B-raf
  • BRAF protein, human
  • Immune Checkpoint Inhibitors